This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
The single domain shark antibody technology and the humanised version (i-body) have been developed into libraries containing a billion or more molecules that can be used to identify binders to a particular target to identify novel drug and diagnostic candidates.
Shark antibodies and i-bodies have high specificity and affinity for various therapeutic and diagnostic targets. They also have a number of advantages compared to traditional antibodies including a unique binding structure, specifically a very long CDR3 loop that can bind into hydrophobic grooves and receptor sites, providing the potential to bind drug targets that cannot be addressed by traditional antibodies. Shark antibodies and i-bodies are naturally small providing an ability to target various diseases more effectively and are manufactured in bacterial systems. Both the shark antibody and i-body are extremely stable at high temperatures and low pH for extended periods of time, giving rise to alternative delivery mechanisms beyond injection.
Alchemia is a drug development company with late stage oncology product pipeline (Phase II and III), and an FDA approved drug (Fondaparinux).
Alchemia's pipeline of oncology products is built on the proprietary platform technology: HyACT
Human Immunodeficiency Virus (HIV);
Vancomycin- and methicillin-resistant bacteria.
In addition to its immunotherapeutics, Bioxyne makes and sells consumer food supplements based on a proprietary probiotic based on a Lactobacillus fermentum strain.